Vaxil Bio Ltd.
VXLLF
$0.13
$0.122,021.31%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -45.29% | 128.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -48.26% | 125.33% | |||
| Operating Income | 48.26% | -125.33% | |||
| Income Before Tax | 153.28% | -210.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 153.28% | -210.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 162.30% | -210.83% | |||
| EBIT | 48.26% | -125.33% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 162.36% | -212.28% | |||
| Normalized Basic EPS | 153.15% | -208.33% | |||
| EPS Diluted | 162.36% | -212.28% | |||
| Normalized Diluted EPS | 153.15% | -208.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||